Aduro Biotech is laying off more than a third of its workforce in a restructuring intended to keep its focus on its cancer drugs now in clinical development.
The corporate shakeup will cut the headcount of Aduro (NASDAQ: ADRO) by... Read more »
Even as retailers struggle with a technology-disrupted business model and changing consumer desires, at least a generally positive overall economy and low unemployment rates seemed to keep shoppers’ wallets open.
But a 2019 that started with stock market losses, a recently... Read more »
Roche this morning added yet another failure to the ever-growing number of experimental Alzheimer’s disease drugs to crumble in late-stage human testing.
The Swiss pharma and partner AC Immune (NASDAQ: ACIU) will stop two Phase 3 studies of their drug... Read more »
Late last week, IBM and several other large companies that serve the healthcare industry announced a collaboration aimed at determining whether, and how, blockchain technology could be used to improve patient care and lower costs for industry stakeholders.
The announcement came... Read more »
Billie, a monthly subscription service for shaving and body care products for women, has raised $25 million.
The New York-based startup said Tuesday that the new funding round, which is being led by Goldman Sachs Private Capital Investing group, brings its... Read more »
In a tech culture that looks toward self-driving cars as the pinnacle of mobility innovation, we’re still debating whether fully autonomous vehicles are an imminent reality for our roads or an ever-receding Shangri-La.
But looking back from the viewpoint of 2019,... Read more »
Plymouth Growth Partners has made another investment in an Indiana tech company.
The Ann Arbor, MI-based venture capital fund has invested an undisclosed amount in Allied Payment Network, which is located in Fort Wayne, IN. Plymouth partner Jeff Barry says the... Read more »
An Eli Lilly drug on the market for a rare form of cancer is now in limbo, after it failed a trial needed to retain the FDA approval the treatment, known as olaratumab (Lartruvo), won two years ago.
Lilly (NYSE: LLY... Read more »
The partial government shutdown, now the longest in U.S. history, began to take a bite out of biotech this week, served with a hot side dish of confusion.
On Tuesday, Aimmune Therapeutics (NASDAQ: AIMT) said the shutdown would delay the... Read more »